相关实验视频

Updated: Jun 12, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

利拉古胺创新:对专利进行全面审查 (2014-2024年)

Ajay Pandey¹, Amit Kumar Goyal¹

¹Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, India.

Pharmaceutical patent analyst

|September 24, 2024

概括

利拉古胺是一种类似葡萄糖类-1 (GLP-1) 激动剂,有效治疗2型糖尿病 (T2DM) 和其并发症. 本综述涵盖了其配方,合成和生物作用.

科学领域:

内分泌学和新陈代谢学
药理学药理学是指药理学的学科.
药物开发药物开发

背景情况:

2型糖尿病 (T2DM) 是一种代谢障碍,其特点是胰岛素抵抗,葡萄糖调节受损,胰岛素分泌减少.
类似葡萄糖类-1 (GLP-1) 是一种对葡萄糖平衡和器官保护有显著影响的隐形素仿真剂.
GLP-1激动剂代表了管理T2DM及其相关并发症的关键治疗类.

研究的目的:

审查liraglutide的药物配方,合成和生物作用.
整合临床试验和关于利拉格卢提德的专利发现.
突出利拉格卢提德作为一种强大的GLP-1激动剂在T2DM管理中的作用.

主要方法:

临床试验的文献评论. 临床试验的文献评论.
分析与利拉格卢提德相关的专利.
关于利拉格卢提德的配方和生物机制的信息的综合.

主要成果:

利拉格卢提德的疗效类似于内源GLP-1的疗效.
审查涵盖了liraglutide的各个方面,从其创建到其体内作用.
临床数据和专利信息支持liraglutide的治疗价值.

结论:

利拉格卢提德是治疗2型糖尿病的有效治疗剂.
了解liraglutide的配方,合成和作用对于其临床应用至关重要.
GLP-1激动剂,以利拉格卢提德为例,为T2DM提供了有价值的治疗策略.

关键词:

生物行动是指生物行动.这就是GLP-1.隐形体模拟的模拟器利拉格卢提德的配方是什么 2 型糖尿病糖尿病类型

更多相关视频

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...